Lonsurf

Monotherapy or in combination w/ bevacizumab for adult patients w/ metastatic CRC who have been previously treated w/ fluoropyrimidine-, oxaliplatin- & irinotecan-based chemotherapy, anti-VEGF biological therapy; & if RAS wild-type, anti-EGFR therapy. Adult patients w/ metastatic gastric or gastroesophageal junction adenocarcinoma who have been previously treated w/ at least 2 prior lines of chemotherapy that included a fluoropyrimidine, platinum, either taxane or irinotecan & if appropriate, HER2/neu-targeted therapy.

Monotherapy or in combination w/ bevacizumab: 35 mg/m² up to a max of 80 mg/dose bd w/in 1 hr of completion of morning & evening meals on days 1-5 & days 8-12 of each 28-day cycle until disease progression or unacceptable toxicity. Severe renal impairment (CrCl 15-29 mL/min) 20 mg/m² (based on trifluridine component) bd on days 1-5 & days 8-12 of each 28-day cycle. Reduce dose to 15 mg/m² bd if unable to tolerate.

Should be taken with food: Take w/in 1 hr after morning & evening meals. Swallow whole.

Cytotoxic Chemotherapy

L01BC59 - trifluridine, combinations ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.

POM